NYSE:MNK Mallinckrodt (MNK) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.04▼$0.0950-Day Range$0.14▼$0.7552-Week Range$0.75▼$6.42Volume1,924 shsAverage Volume2.62 million shsMarket Capitalization$1.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Mallinckrodt (NYSE:MNK) StockMallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.Read More MNK Stock News HeadlinesSeptember 20, 2023 | msn.comFirm Retention Summary: MallinckrodtSeptember 20, 2023 | msn.comDrug giant Mallinckrodt enters second Irish ExaminershipOctober 2, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. September 19, 2023 | msn.comBankrupt Drugmaker Mallinckrodt Considers Sale of Opioid BusinessSeptember 1, 2023 | benzinga.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)August 31, 2023 | finance.yahoo.comMallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)August 30, 2023 | finance.yahoo.comMallinckrodt Receives Court Approval for "First Day" Motions to Support Ongoing OperationsAugust 28, 2023 | msn.comMallinckrodt files for bankruptcy for a second timeOctober 2, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.August 28, 2023 | finance.yahoo.comNYSE American to Commence Delisting Proceedings Against Mallinckrodt plc (MNK)August 28, 2023 | bizjournals.comMallinckrodt bankruptcy shows millions owed to NC firms, stateAugust 28, 2023 | msn.comMallinckrodt discloses grand jury subpoena, makes bankruptcy filing officialAugust 28, 2023 | msn.comHit By Opioid Lawsuits Mallinckrodt Files For Second Bankruptcy In Just Three YearsAugust 28, 2023 | bizjournals.comDrug maker Mallinckrodt again files for bankruptcy, as plannedAugust 28, 2023 | benzinga.comCalling All Mallinckrodt plc (MNK) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your LossesAugust 28, 2023 | nasdaq.comMallinckrodt Initiates Voluntary Prepackaged Chapter 11 Proceedings In U.S. Bankruptcy CourtAugust 28, 2023 | msn.comDrugmaker Mallinckrodt files for second bankruptcy in the USAugust 28, 2023 | finance.yahoo.comMallinckrodt plc Takes Next Step to Implement Comprehensive Financial Restructuring Plan to Address Long-Term Debt and Opioid ObligationsAugust 24, 2023 | msn.comMallinckrodt Lenders to Take Control in Bankruptcy That Cuts $1 Billion in Opioid PaymentsAugust 23, 2023 | bizjournals.comDrug maker Mallinckrodt to again file for bankruptcy protectionAugust 23, 2023 | msn.comMallinckrodt second bankruptcy would cut $1 billion from opioid settlementAugust 23, 2023 | markets.businessinsider.comMallinckrodt Inks RSA To Initiate Voluntary Prepackaged Chapter 11 ProceedingsAugust 23, 2023 | markets.businessinsider.comMallinckrodt To Initiate Chapter 11 Bankruptcy ProceedingsAugust 23, 2023 | msn.comU.S. drugmaker Mallinckrodt plans to file for bankruptcy protectionAugust 23, 2023 | proactiveinvestors.comMallinckrodt stock tumbles on plans to file for Chapter 11 bankruptcy for second time in three yearsAugust 23, 2023 | msn.comMallinckrodt to file for prepackaged Chapter 11 bankruptcy and cut about $1.9 billion in debtAugust 23, 2023 | msn.com150-Year Old Opioid Drugmaker Mallinckrodt Files For Bankruptcy For Second TimeSee More Headlines Receive MNK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter. Email Address MNK Company Calendar Last Earnings8/09/2023Today10/02/2023Next Earnings (Estimated)12/18/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:MNK CUSIPN/A CIK1567892 Webwww.mallinckrodt.com Phone(531) 696-0000FaxN/AEmployees2,700Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($116.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net Margins-82.59% Pretax MarginN/A Return on Equity20.32% Return on Assets2.49% Debt Debt-to-Equity Ratio1.18 Current Ratio0.57 Quick Ratio0.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$47.48 per share Price / Book0.00Miscellaneous Outstanding Shares13,170,000Free Float13,131,000Market Cap$1.12 million OptionableOptionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMark C. TrudeauPresident, Chief Executive Officer & DirectorBryan M. ReasonsChief Financial Officer & Executive Vice PresidentSteven Joseph RomanoChief Scientific Officer & Executive VPBabatunde Adekunle OtulanaChief Medical Officer & Senior Vice PresidentMichele RobertsonChief Compliance Officer & Senior Vice PresidentKey CompetitorsEvofem BiosciencesNASDAQ:EVFMNeptune Wellness SolutionsNASDAQ:NEPTNovanNASDAQ:NOVNQNovanNASDAQ:NOVNOncorusNASDAQ:ONCRView All CompetitorsInsiders & InstitutionsHudson Bay Capital Management LPSold 100,000 shares on 8/15/2023Ownership: 7.909%Goldman Sachs Group Inc.Sold 207,351 shares on 8/15/2023Ownership: 0.257%State Street CorpBought 34,700 shares on 8/14/2023Ownership: 0.705%JPMorgan Chase & Co.Sold 365,378 shares on 8/11/2023Ownership: 9.994%National Bank of Canada FIBought 27,731 shares on 7/26/2023Ownership: 0.211%View All Insider TransactionsView All Institutional Transactions MNK Stock - Frequently Asked Questions When is Mallinckrodt's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, December 18th 2023. View our MNK earnings forecast. How were Mallinckrodt's earnings last quarter? Mallinckrodt plc (NYSE:MNK) issued its earnings results on Wednesday, August, 9th. The company reported ($1.45) earnings per share for the quarter. The firm earned $475 million during the quarter. Mallinckrodt had a positive trailing twelve-month return on equity of 20.32% and a negative net margin of 82.59%. What guidance has Mallinckrodt issued on next quarter's earnings? Mallinckrodt issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.70 billion-$1.82 billion. What other stocks do shareholders of Mallinckrodt own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Endo International (ENDP), Teva Pharmaceutical Industries (TEVA), Gerdau (GGB), AT&T (T), Alibaba Group (BABA), Advanced Micro Devices (AMD). What is Mallinckrodt's stock symbol? Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK." What is Mallinckrodt's stock price today? One share of MNK stock can currently be purchased for approximately $0.09. How much money does Mallinckrodt make? Mallinckrodt (NYSE:MNK) has a market capitalization of $1.12 million. How many employees does Mallinckrodt have? The company employs 2,700 workers across the globe. How can I contact Mallinckrodt? Mallinckrodt's mailing address is COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15. The official website for the company is www.mallinckrodt.com. The company can be reached via phone at (531) 696-0000 or via email at investor.relations@mnk.com. This page (NYSE:MNK) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mallinckrodt plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.